Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Genfit SA

Take Five: Ipsen Bags Rights To Day One Brain Cancer Drug

The Paris-based group has inked five external deals already this year, this time paying $111m to get access internationally to Day One Biopharmaceuticals' Ojemda for refractory pediatric low-grade glioma.

Deals Cancer

EU Moment Of Truth For Lecanemab & 14 Other Drugs

Eisai/Biogen could this week learn whether the European Medicines Agency will give the thumbs up to market lecanemab across the EU for early Alzheimer’s disease.

Europe Drug Review

Ipsen Gets Ahead Of The Qirv in Cholangitis

Iqirvo gains accelerated approval, but Gilead’s seladelpar is probably only two months behind.

Approvals Commercial

Ipsen Dealmaking Heats Up With Marengo Cold Tumor Collaboration

The France-based mid-sized drugmaker has solidified its pipeline through several external pacts in the past few years and its dealmaking is showing no signs of slowing down.

Business Strategies Oncology
See All

Company Information

  • Industry
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
UsernamePublicRestriction

Register